Immunome IMNM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.49M+83.3% | $2.96M+8.8% | $2.68M-21.7% | $3.08M-20.7% | $3M+6.7% | ||
| $0-100% | $0-100% | $0-100% | $4.02M+69.8% | $2.93M+184% | ||
| $46.38M+25.8% | $50.77M+6.0% | $49.19M+32.2% | $40.45M+39.1% | $36.87M+140% | ||
| $12.95M+21.1% | $12.09M+15.7% | $10.95M+14.9% | $10.04M+43.9% | $10.69M+78.0% | ||
| $59.33M+24.7% | $72.86M-15.0% | $60.14M+12.6% | $50.49M+19.2% | $47.56M-64.3% | ||
| -$59.33M-32.9% | -$72.86M+12.2% | -$60.14M-19.0% | -$46.48M-16.2% | -$44.64M+66.3% | ||
| -$53.84M-29.3% | -$69.9M+12.9% | -$57.46M-22.0% | -$43.4M-20.1% | -$41.64M+67.8% | ||
| -$0.48+7.7% | -$0.75+41.4% | -$0.65+16.7% | -$0.50+16.7% | -$0.52+79.3% | ||
| -$0.48+7.7% | -$0.75+41.4% | -$0.65+16.7% | -$0.50+16.7% | -$0.52+79.3% | ||
| 113.1M+42.5% | 87.4M+49.0% | 88M+46.1% | 87M+45.2% | 79.4M+54.1% | ||
| 113.1M+42.5% | 87.4M+49.0% | 88M+46.1% | 87M+45.2% | 79.4M+54.1% | ||
| —— | —— | —— | —— | —— | ||
| -$53.84M-29.1% | -$69.9M+12.9% | -$57.43M-22.1% | -$43.42M-20.2% | -$41.7M+67.8% | ||
| -$0+100% | —— | $24K-64.7% | —— | -$60K— | ||
| $5.49M+83.3% | $2.96M+8.8% | $2.68M-21.7% | $3.08M-20.7% | $3M+6.7% | ||
| $0-100% | $0-100% | $0-100% | $4.02M+69.8% | $2.93M+184% | ||
| -$59.33M-32.9% | -$72.86M+12.2% | -$60.14M-19.0% | -$46.48M-16.2% | -$44.64M+66.3% | ||
| -$58.73M-33.4% | -$72.23M+12.5% | -$59.55M-18.8% | -$45.84M-16.2% | -$44.03M+66.7% | ||
| -$58.73M-33.4% | -$72.23M+12.5% | -$59.55M-18.8% | -$45.84M-16.2% | -$44.03M+66.7% | ||
| -$59.33M-32.9% | -$72.86M+12.2% | -$60.14M-19.0% | -$46.48M-16.2% | -$44.64M+66.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Immunome's income statement data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.